Decision Resources Research Reports

Title	Published	Price
Ankylosing Spondylitis: How Have Biological Therapies Affected the Market? By: Decision Resources Introduction The availability of TNF-á inhibitors fueled a tremendous year-on-year increase in the ankylosing spondylitis (AS) market from 2006 to 2007, and we expect signifi cant growth to continue over the next ten years. Although \| more...	3/23/2009	$2,250.00
The Drug Class Impact of Major Patent Expirations By: Decision Resources Introduction The increasing pressure on physicians to prescribe generics rather than other patent-protected agents within the same drug class presents a signifi cant threat to the pharmaceutical industry. This report, which features 34 fi \| more...	3/11/2009	$2,250.00
SPECIAL REPORT: State of the Pharmaceutical Industry, 2009 By: Decision Resources Introduction Change will be the only certainty in 2009 as economic reality dictates hard decisions and new approaches for the pharma industry. Disruptive change—the kind that happens once in a couple of decades or longer—can \| more...	2/24/2009	$4,500.00
Narrowing the Innovation Gap with Fragment-Based Drug Discovery and Design By: Decision Resources Introduction Fragment-based drug discovery and design technology could dramatically improve the prospects of identifying suitable development compounds and feed withering clinical pipelines. These technologies have already generated several interesting compounds. If successful, fragment-based design could \| more...	2/18/2009	$2,250.00
Strategic Overview of Pricing and Reimbursement in the Major Markets By: Decision Resources Around the world, the market success of branded drugs is influenced by changes in healthcare systems and the growing role of payers - and at this point in time, economic concerns are prompting waves of \| more...	2/12/2009	$14,500.00
Market Access, Pricing, and Reimbursement News in the Fourth Quarter of 2008 By: Decision Resources Introduction In an increasingly hostile economic climate, governments and other payers are redoubling their efforts to curb their pharmaceutical expenditures. In addition to measures to maximize the use of inexpensive generics, payers are seeking new \| more...	1/30/2009	$2,250.00
Are There Changes Ahead for the Generalized Anxiety Disorder Market? By: Decision Resources Introduction Generalized anxiety disorder (GAD) is a prevalent psychiatric disorder in the major pharmaceutical markets, and drug therapy is considered the most effective treatment. The therapy market for GAD is crowded and includes many generic \| more...	1/26/2009	$2,250.00
Special Report: Lessons Learned: Top Events Impacting the Pharmaceutical Industry in 2008 By: Decision Resources 2008 will come to be known as the year when real change started to take hold across the pharmaceutical industry. Though the year began with a more cost-conscious environment complete with downsizing and restructuring announcements, \| more...	12/22/2008	$4,500.00
It’s All About the Biomarkers: How 2008’s Biomarker-Based Partnering Is Driving Personalized Medicine By: Decision Resources Despite the ongoing economic crisis, 2008 was an active year for partnering and M&As involving pharmaceutical and diagnostics companies. Academic institutions, governmental bodies, and smaller biomarker discovery companies also penned alliances with industry players. Novel \| more...	12/17/2008	$2,250.00
Enabling Oncology Diagnostics: Predictive Biomarkers Based on Genes, Proteins, and Pathways By: Decision Resources According to the American Cancer Society, new cancer diagnoses will reach approximately 1.4 million in 2008 in the United States alone. Cancer treatment typically involves surgery, radiation therapy, and/ or chemotherapy; however, the high rate \| more...	12/17/2008	$2,250.00
Autoimmune Disease Series: Strategies for Success in the Challenging Sjögren’s Syndrome Market By: Decision Resources Sjögren’s syndrome (SS) is one of the most common autoimmune diseases, affecting more than 1 million individuals in the United States. Although the majority of cases are relatively benign, in more-severe cases, patients can develop \| more...	12/16/2008	$4,500.00
Emerging Blockbusters: 2009’s Most Promising Drugs and the Future of the Blockbuster Model By: Decision Resources In 2007, 111 blockbuster drugs (drugs with more than $1 billion in annual sales) were on the market and generated more than $250 billion in revenue. These high-value products are fundamental to the success and \| more...	12/16/2008	$2,250.00
What to Do When the R&D Pipeline Runs Dry By: Decision Resources The pharmaceutical industry is under signifi cant pressure to improve its bottom line and growth prospects. Industry stakeholders are seriously discussing whether companies should adopt a new business model to improve their outlook. Much of \| more...	12/9/2008	$2,250.00
U.S. Pharma Pricing Strategies: Case Studies and Future Considerations By: Decision Resources The U.S. pharmaceutical marketplace unquestioningly features the least restricted pricing environment of the seven major pharmaceutical markets covered by Decision Resources (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). A free-pricing \| more...	12/9/2008	$2,250.00
Autoimmune Disease Series: Will Biologics Emerge as New Treatments for Reactive Arthritis? By: Decision Resources Introduction Reactive arthritis (ReA), a seronegative spondyloarthropathy that is believed to be partially autoimmune and triggered by the presence of a bacterial infection, is rare. For that reason, along with the availability of generic agents \| more...	12/5/2008	$4,500.00
Pharmaceutical Pricing and Reimbursement in the United Kingdom, 2008 By: Decision Resources Introduction The pharmaceutical industry has long criticized the slow uptake of new medicines in the United Kingdom. Beginning January 1, 2009, the U.K. government plans to implement measures to accelerate and widen access to innovative \| more...	12/4/2008	$2,250.00
What Is the Future Role of Predictive Safety Biomarkers in Drug Development? By: Decision Resources Introduction Predictive safety biomarkers are categorized by their target action—predicting drug toxicity, selecting patients for treatment, or predicting treatment effi cacy. Increasingly, diagnostics developers and pharmaceutical companies are collaborating on biomarker identifi cation and validation. \| more...	12/3/2008	$2,250.00
Pricing and Reimbursement of Fixed-Dose Combination Drugs in the United States By: Decision Resources Introduction Fixed-dose combinations (FDCs) of prescription drugs can prove clinically useful where polypharmacy is required—for example, in the management of HIV, asthma, and cardiometabolic disorders such as diabetes, dyslipidemia, and hypertension. These products also offer \| more...	12/3/2008	$2,250.00
Meeting the Challenges of Manufacturing Biosimilars By: Decision Resources Introduction Branded biologics have, until recently, been immune to generics competition; however, the approval of biosimilars in Europe heralds a changing landscape. Legislation enabling the approval of biosimilars is stalled in the U.S. Congress but \| more...	11/25/2008	$2,250.00
Fulfilling the Promise of Personalized Medicine Through Next-Generation Sequencing By: Decision Resources Introduction The pharmaceutical industry has long criticized the slow uptake of new medicines in the United Kingdom. Beginning January 1, 2009, the U.K. government plans to implement measures to accelerate and widen access to innovative \| more...	11/24/2008	$2,250.00
Tropical Diseases: Treatment, Prevention, and Market Opportunities By: Decision Resources Introduction Increased travel and environmental changes are likely to accelerate the spread of tropical infectious diseases such as malaria, dengue fever, yellow fever, and Japanese encephalitis. To stop this advance, more-effective treatments and vaccines are \| more...	11/21/2008	$2,250.00
Value-Added Pharma: How to Accomplish the Impossible By: Decision Resources Introduction The pharma industry is constantly being told that it needs to improve its bottom line and the way it does business. Pressures are mounting for more innovative drugs, less expensive drugs, and the wider \| more...	11/20/2008	$2,250.00
Pharma's Changing Business Strategies: Five Deadly Pharma Sins By: Decision Resources Although much of the pharma industry is seemingly poised like deer in the headlights when it comes to transformational change, signs suggest that some companies have taken up the message that the future is not \| more...	10/30/2008	$2,250.00
Effective Drug Life Cycle Management: The Crucial Interaction Between Brand Life Span and Market Life Cycle By: Decision Resources Introduction Pharmaceutical companies recognize the importance of life cycle management but often focus on their own brands without taking note of the all-important market life cycle. Companies need to understand how the three stages \| more...	9/30/2008	$2,250.00
Pharma and the Feds: Key Government Activities and How They Affect the Biopharmaceutical Industry By: Decision Resources Introduction This is a critical time in U.S. history for examination of the delivery of healthcare services. Some 47 million people in the United States lack healthcare coverage; the country spends $2.2 trillion \| more...	9/30/2008	$2,250.00
Title	Published	Price

< prev 1 2 3 4 5 6 7 8 9 10 next >

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/22/2009 - 3